Literature DB >> 35909408

Severity and outcome of COVID-19 disease in patients with allergic rhinitis during the pandemic in Qatar - A preliminary report.

Sami Aqel1, Tayseer Ibrahim1, Salma Taha1, Hassan Mobayed1, Maryam Al-Nesf1.   

Abstract

BACKGROUND: Allergic rhinitis and asthma exacerbation are strongly linked to respiratory viral and bacterial infections. COVID-19 pandemic has raised concerns about the risk of infection and the severity of COVID-19 infection in patients with asthma and allergic rhinitis. However, increasing evidence suggests that atopic disease protects against severe COVID-19 illness owing to the underlying type 2 inflammatory process. Many studies have reported the impact of asthma on COVID-19 disease; however, data on allergic rhinitis are scarce. In this study, we aimed to investigate the severity and outcome of COVID-19 disease in adult patients with allergic rhinitis in Qatar during the first pandemic wave.
METHODS: We conducted a retrospective chart review of adult patients with a confirmed diagnosis of asthma and/or allergic rhinitis who had a positive COVID-19 RT-PCR between February 01, 2020, and December 01, 2020. Parameters evaluated included the WHO classification of COVID-19 disease severity as mild, moderate, severe, and critical; COVID-19 disease outcome; and mortality. Patients with allergic rhinitis were defined as those with typical allergic rhinitis symptoms and positive skin prick test or specific IgE to perennial or seasonal inhaled allergens. Only data about patients with allergic rhinitis has been presented in this report.
RESULTS: We screened 97 EMR Cerner records of patients who had the diagnosis code for allergic rhinitis. Nine patients met the inclusion criteria of allergic rhinitis diagnosis; the remaining either had no allergy testing or had negative allergy tests. Seven (77.7%) patients had mild COVID-19, whereas only one (11.1%) patient each had moderate and severe disease. The length of hospital stays for 6 patients ranged from 5-13 days, and the remaining 3 patients were quarantined at home. No reports of critical cases or death were identified. All the patients recovered from COVID-19 with a favorable outcome.
CONCLUSION: This preliminary data showed that most patients with allergic rhinitis had mild COVID-19 disease. Furthermore, all of them recovered well, similar to the available data from previous studies. A limitation of this study is the small population size. © 2022 Aqel, Ibrahim, Taha, Mobayed, Al-Nesf, licensee HBKU Press.

Entities:  

Keywords:  COVID-19; allergic rhinitis; disease severity

Year:  2022        PMID: 35909408      PMCID: PMC9284599          DOI: 10.5339/qmj.2022.fqac.8

Source DB:  PubMed          Journal:  Qatar Med J        ISSN: 0253-8253


Table 1

Characteristics of 9 patients with allergic rhinitis and COVID-19 disease

Patient Age (years) Gender Comorbidities Total IgE (kU/L) Inhaled allergens Length of hospital (days) Type of quarantine stay COVID-19 severity

1 37MaleDiabetes hypertension Chronic rhinosinusitis751Aspergillus, DF11Quarantine facilityMild

2 46MaleChronic rhinosinusitis111DF, DP13Quarantine facilityMild

3 39MaleChronic rhinosinusitis192DF, DP Home quarantineMild

4 53MaleChronic rhinosinusitis Bronchial asthma600-6In-patient medical wardModerate

5 36MaleChronic rhinosinusitis793grass pollens mix, weed pollens, DF, DP13Quarantine facilityMild

6 38MaleHypertension Chronic rhinosinusitis OSA121DF, DP and cockroaches14Both in-patient medical ward and Quarantine facilitySevere

7 38MaleChronic rhinosinusitis340(Grass pollens mix, Bermuda grass, weed pollens, aspergillus, DF, DP, cockroaches)13Quarantine facilityMild

8 32FemaleChronic rhinosinusitis-DF, DP Home QuarantineMild

9 28MaleChronic rhinosinusitis213NA Home QuarantineMild

DF: Dermatophagoides farinae (American dust mite), DP: Dermatophagoides pteronyssinus (European dust mite), OSA: Obstructive sleep apnea.

  3 in total

Review 1.  Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review.

Authors:  N G Papadopoulos; I Christodoulou; G Rohde; I Agache; C Almqvist; A Bruno; S Bonini; L Bont; A Bossios; J Bousquet; F Braido; G Brusselle; G W Canonica; K H Carlsen; P Chanez; W J Fokkens; M Garcia-Garcia; M Gjomarkaj; T Haahtela; S T Holgate; S L Johnston; G Konstantinou; M Kowalski; A Lewandowska-Polak; K Lødrup-Carlsen; M Mäkelä; I Malkusova; J Mullol; A Nieto; E Eller; C Ozdemir; P Panzner; T Popov; S Psarras; E Roumpedaki; M Rukhadze; A Stipic-Markovic; A Todo Bom; E Toskala; P van Cauwenberge; C van Drunen; J B Watelet; M Xatzipsalti; P Xepapadaki; T Zuberbier
Journal:  Allergy       Date:  2010-11-18       Impact factor: 13.146

Review 2.  The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19.

Authors:  Ya-Dong Gao; Ioana Agache; Mübeccel Akdis; Kari Nadeau; Ludger Klimek; Marek Jutel; Cezmi A Akdis
Journal:  Int Immunol       Date:  2022-03-25       Impact factor: 4.823

Review 3.  A compendium answering 150 questions on COVID-19 and SARS-CoV-2.

Authors:  Carmen Riggioni; Pasquale Comberiati; Mattia Giovannini; Ioana Agache; Mübeccel Akdis; Magna Alves-Correia; Josep M Antó; Alessandra Arcolaci; Ahmet Kursat Azkur; Dilek Azkur; Burcin Beken; Cristina Boccabella; Jean Bousquet; Heimo Breiteneder; Daniela Carvalho; Leticia De Las Vecillas; Zuzana Diamant; Ibon Eguiluz-Gracia; Thomas Eiwegger; Stefanie Eyerich; Wytske Fokkens; Ya-Dong Gao; Farah Hannachi; Sebastian L Johnston; Marek Jutel; Aspasia Karavelia; Ludger Klimek; Beatriz Moya; Kari C Nadeau; Robyn O'Hehir; Liam O'Mahony; Oliver Pfaar; Marek Sanak; Jürgen Schwarze; Milena Sokolowska; María J Torres; Willem van de Veen; Menno C van Zelm; De Yun Wang; Luo Zhang; Rodrigo Jiménez-Saiz; Cezmi A Akdis
Journal:  Allergy       Date:  2020-07-20       Impact factor: 14.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.